drug · antibody drug conjugate
patient view →patritumab deruxtecan
Phase 3updated 2mo agoby Daiichi Sankyo Co Ltd🔗 ChEMBL
Phase 3community read0 votes
Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and 6 investigational indications.
indications
indications
NSCLC
targets
Receptor tyrosine-protein kinase erbB-3DNA topoisomerase 1
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that